Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma

Medical Oncology
Jianhua LiShuijun Zhang

Abstract

Hepatotoxicity induced by sorafenib and antiviral therapy is a limitation for its continuation treatment for patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC). This prospective study determined the efficacy of tiopronin in hepatotoxicity prevention of HBV-related HCC treatment. Eighty-two patients (median age, 50 years; 71 % male) of advanced HCC treated with sorafenib and antiviral therapy were included, of whom 40 were given the supplementation of tiopronin. The primary endpoint was liver function which was checked before the treatment and every week during the therapy. Besides, course discontinuations, dose reductions, HBV DNA levels and treatment efficacy were evaluated. Patient characteristics and liver function were comparable (p > 0.05). The proportion of abnormal liver function was significantly lower in tiopronin group than in control group including alanine transaminase (ALT, p = 0.035), aspartate aminotransferase (AST, p = 0.041), total bilirubin (TBIL, p = 0.021) and albumin (ALB, p = 0.001). Rates of course discontinuations (p = 0.024) and dose reductions (p = 0.046) were significantly lower in tiopronin groups, and disease control rate (p = 0.036) was higher. No difference was found i...Continue Reading

References

Sep 1, 1987·American Journal of Epidemiology·A S LokH J Lin
Dec 1, 1981·Agents and Actions·F Capasso
Jan 1, 1994·European Journal of Clinical Pharmacology·M S CarlssonS Lindgren
Apr 30, 1999·BMJ : British Medical Journal·D G Altman, J M Bland
Oct 27, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases
Apr 4, 2007·Antimicrobial Agents and Chemotherapy·Brenda I Hernandez-SantiagoRaymond F Schinazi
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Sep 18, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Inmaculada Castro BezaM Isabel Villanego Beltrán
Feb 17, 2009·Lancet·Yun-Fan Liaw, Chia-Ming Chu
Jan 14, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Bruno VincenziGiuseppe Tonini
Dec 29, 2011·Journal of Hepato-biliary-pancreatic Sciences·Yorihisa UrataShigefumi Suehiro
Aug 29, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric I ZimmermanSharyn D Baker
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 23, 2015·Journal of Gastroenterology and Hepatology·Seungtaek LimHye Jin Choi
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Feb 14, 2015·Liver International : Official Journal of the International Association for the Study of the Liver·Yu YangQiu Li

❮ Previous
Next ❯

Citations

Jun 15, 2017·World Journal of Gastroenterology : WJG·Lin-Ling JuJian-Guo Shao
Dec 13, 2019·Infectious Agents and Cancer·Wu ShanshanChen Feng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.